IPHA
Innate Pharma·NASDAQ
--
--(--)
--
--(--)
4.99 / 10
Netural
Fund flow analysis scores 7.28/10, indicating robust liquidity with positive trends in block, medium, large, and extra-large flows, though small flows are negative. Analyst sentiment is overwhelmingly bullish (Strong Buy at 100% from 2 researches), but historical win rates vary widely (0% to 60%). This mix of strong fund inflows and bullish analyst views provides some support, yet inconsistent historical performance tempers conviction.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-10-29
InstitutionBTIG
Times predicted1
Historical Win Rate0.0%
What is the market sentiment for IPHA?
- IPHA holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 4.99/10 (Netural).
